You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1367-ESGO Clinical and survival data of early-stage tubo-ovarian carcinoma according to BRCA mutational status. A large, multicenter, retrospective study

Article Text

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1367-ESGO Clinical and survival data of early-stage tubo-ovarian carcinoma according to BRCA mutational status. A large, multicenter, retrospective study
Free
  1. Claudia Marchetti1,
  2. Beyhan Ataseven2,
  3. Anna Myriam Perrone3,
  4. Chiara Cassani4,
  5. Robert Fruscio5,
  6. Carolina Maria Sassu6,
  7. Adriana Ionelia Apostol6,
  8. Philipp Harter2,
  9. Alexander Traut2,
  10. Pierandrea de Iaco3,
  11. Eloisa Arbustini7,
  12. Nicolò Bizzarri6,
  13. Stephanie Schneider2,
  14. Kerstin Rhiem8,
  15. Marco Di Stanislao3,
  16. Mario Urtis7,
  17. Angelo Minucci6,
  18. Giovanni Scambia1 and
  19. Anna Fagotti1
  1. 1Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS. Department of Health Sciences and Public Health Catholic University of Sacred Heart, Rome, Italy
  2. 2Department of Gynecology and Gynecological Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany
  3. 3Division of Oncologic Gynecology, Azienda Ospedaliero-Universitaria di Bologna, IRCSS, Bologna, Italy
  4. 4Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Unit of Obstetrics and Gynecology, IRCCS San Matteo Hospital Foundation, Pavia, Italy
  5. 5Department of Medicine and Surgery, University of Milan-Bicocca, MILAN, Italy
  6. 6Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
  7. 7Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sci, IRCCS San Matteo Hospital Foundation, PAVIA, Italy
  8. 8Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany

Abstract

Introduction/Background The impact of BReast CAncer genes (BRCA) status on early-stage ovarian cancer (eOC) survival has rarely been investigated. Therefore, the possible efficacy of Poly (ADP-ribose) polymerase inhibitors (PARPi) in this population is unexplored. Since the risk of recurrence in eOC is low but not absent, understanding the role of BRCA mutations in eOC could allow a more tailored approach.

Methodology Data of patients with a diagnosis of epithelial eOC (International Federation of Gynecology and Obstetrics FIGO stage I-II) between 2011–2019 with known BRCA status were collected from 5 centers in Europe. Results by the BRCA status were compared.

Abstract 2022-RA-1367-ESGO Figure 1
Abstract 2022-RA-1367-ESGO Figure 1

Progression-free survival and overall survival in patients with early-stage OC according to BRCA status

Results 369 patients were included, 110 (29.8%) with BRCA mutation (BRCAm) and 259 (70.2%) BRCA wild-type (BRCAwt). The two groups were homogeneous regarding age at disease presentation (table 1). As expected, high-grade serous histotype was significantly more frequent in BRCAm women (p<0.001). BRCAm patients presented as a stage II in 46.4% of the cases, compared with 35.3% in BRCAwt group (p < 0.03). The majority of patients in the BRCAm group received a carboplatin-paclitaxel based treatment (81.5%) compared with 59.4% in the BRCAwt group. After a median follow-up of 45 months, recurrences were significantly more frequent in BRCAm population (32.7%) compared with BRCAwt (23.6%) (p < 0.04). There was no difference between the two groups in terms of median Progression-Free Survival (PFS) (BRCAm 79 months vs BRCAwt Not Reached, p < 0.36, figure 1a) and overall survival (OS) (median OS Not Reached for both groups; p < 0.25, figure 1b).

View this table:
Abstract 2022-RA-1367-ESGO Table 1

Clinical characteristics of patients, according to BRCA mutational status

Conclusion No statistically significant differences in survival according to BRCA status were observed in eOC. The higher relapse rate in BRCAm patients does not affect OS, and can be explained with the use of PARPi or secondary surgery at recurrence. A specific analysis for HGSOC eOC population has already been planned.

https://doi.org/10.1136/ijgc-2022-ESGO.701

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.